Quarterly report pursuant to Section 13 or 15(d)

BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of preliminary purchase consideration (Details)

v3.23.1
BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of preliminary purchase consideration (Details) - USD ($)
 1 Months Ended 3 Months Ended
Feb. 21, 2023
Apr. 30, 2022
Mar. 31, 2023
Mar. 31, 2022
Cash consideration:        
Net cash consideration     $ 2,995,000 $ 0
Kind Therapeutics USA LLC.        
Cash consideration:        
Cash paid at closing   $ 10,128,000    
Cash paid at closing   13,500,000    
Release of escrow   2,444,000    
Severance paid from escrow   556,000    
Less cash acquired   (2,310,000)    
Net cash consideration   10,818,000    
Note payable   5,634,000    
Write-off accounts receivable   658,000    
Write-off of deferred accounts receivable   842,000    
Total fair value of consideration transferred   $ 17,952,000    
Ermont Acquisition        
Cash consideration:        
Cash paid at closing $ 3,000,000      
Less cash acquired (5,000)      
Net cash consideration 2,995,000      
Note payable 4,569,000      
Total fair value of consideration transferred $ 10,558,000   $ 13,000,000